(:TLGT)

Oct 14, 2021 11:00 am ET
Thinking about buying stock in NRX Pharmaceuticals, Teligent, BioXcel Therapeutics, FuelCell Energy, or United States Steel?
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRXP, TLGT, BTAI, FCEL, and X.
Oct 14, 2021 06:15 am ET
Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process
BUENA, N.J., Oct. 14, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company ("Teligent" or the "Company"), today announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware to pursue a sale process that is intended to maximize the value of the Company.
Sep 10, 2021 10:35 am ET
Thinking about buying stock in SOS Ltd, VICI Properties, Gevo, Up Fintech, or Teligent?
NEW YORK, Sept. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOS, VICI, GEVO, TIGR, and TLGT.
Aug 16, 2021 07:00 am ET
Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. “Product demand in our core business was impacted by a...
Aug 11, 2021 04:05 pm ET
Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021
Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June...
Jun 30, 2021 11:00 am ET
Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders
Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021 and adjourned to June 30, 2021, was convened and...
Jun 18, 2021 11:00 am ET
Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders
Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being...
May 25, 2021 07:00 am ET
Teligent, Inc. Announces First Quarter 2021 Earnings Report and Provides Business Update
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and provided a business update. “As we prepare for the second half of 2021, we are pleased with...
May 21, 2021 04:30 pm ET
Teligent, Inc. to Hold Conference Call for First Quarter 2021 Financial Results on Tuesday May 25, 2020
Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Tuesday, May 25th, 2021 to discuss the first quarter ended March 31,...
May 03, 2021 06:45 pm ET
Teligent, Inc. Announces 2020 Year-End Earnings Report and Provides Business Update
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2020. “We are pleased with the progress our team has made at Teligent....
Apr 15, 2021 07:30 am ET
Teligent Announces Hiring of Chief Financial Officer
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective...
Feb 23, 2021 06:30 am ET
Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors
BUENA, N.J., Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors, effective immediately. Mr. Pate will serve on the Audit and Nominating and Corporate Governance Committees.
Feb 16, 2021 06:30 am ET
Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors
BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries.
Jan 28, 2021 05:00 am ET
Teligent Takes Strategic Steps to Recapitalize and Position Business for Success
BUENA, N.J., Jan. 28, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced a series of strategic actions in partnership with its senior lenders and its Series C noteholders to recapitalize and enhance the Company's financial flexibility. Through these actions and with support from its senior lenders and Series C noteholders, the Company is strengthening its balance sheet while also working to raise additional capital and position itself for success, including enabling it to complete the
Jan 22, 2021 09:00 am ET
Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq...
Dec 31, 2020 03:20 pm ET
Teligent, Inc. Announces Third Quarter 2020 Results
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020. Financial Highlights Third Quarter...
Dec 14, 2020 09:45 am ET
Thinking about buying stock in Teligent, Synlogic, Norwegian Cruise Line, AMC Entertainment, or Virgin Galactic?
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TLGT, SYBX, NCLH, AMC, and SPCE.
Nov 25, 2020 12:00 pm ET
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020, adjourned to November 11, 2020 and then to...
Nov 11, 2020 10:54 am ET
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020 and adjourned to November 11, 2020, was convened...
Oct 22, 2020 11:25 am ET
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020, was convened and adjourned without any business...
Oct 02, 2020 01:38 pm ET
TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ:
Sep 23, 2020 08:50 am ET
Teligent Announces Completion of Series D Convertible Note Exchange
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 million aggregate principal amount of Zero Coupon Convertible...
Aug 19, 2020 07:30 am ET
Teligent, Inc. Announces Second Quarter 2020 Results
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2020. Financial Highlights Second Quarter 2020 vs. First Quarter 2020...
Aug 14, 2020 08:30 am ET
Teligent, Inc. to Hold Conference Call for Second Quarter 2020 Financial Results and Business Update on Wednesday August 19th, 2020
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19th, 2020 to discuss the 2nd quarter 2020 financial results and business...
Jul 20, 2020 04:05 pm ET
Teligent Announces Completion of Series C Convertible Note Financing and Exchange
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of $13.8 million aggregate principal amount of 9.5% Series C Senior Convertible Notes...
Jul 20, 2020 08:45 am ET
Teligent, Inc. Announces the Appointment of John Celentano as Chairman of the Board
Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announce that John Celentano, a current independent director of Teligent, has been appointed Chairman of...
Jul 17, 2020 08:45 am ET
Teligent, Inc. Announces Hiring of Chief Legal Officer and Corporate Secretary
Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced the hiring of Philip Yachmetz as Chief Legal Officer and Corporate Secretary of the Company, effective July...
Jun 22, 2020 04:15 pm ET
Teligent Regains Compliance with NASDAQ Listing Requirements
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today that it received notice from The NASDAQ Stock Market LLC (“NASDAQ”) on June 18, 2020 indicating that the...
Jun 03, 2020 04:15 pm ET
Teligent Announces Conversion Rate Adjustment for its 7.0% Cash / 8.0% PIK Series B Senior Unsecured Convertible Notes Due 2023 and its 4.75% Convertible Senior Notes Due 2023
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today conversion rate adjustments for the Company’s 7.0% Cash / 8.0% PIK Series B Senior Unsecured Convertible Notes...
May 26, 2020 04:30 pm ET
Teligent Announces One-for-Ten Reverse Stock Split
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today that as of 12:01 a.m., Eastern Time, on May 28, 2020 it will effect a one-for-ten reverse stock split of its...
May 22, 2020 07:30 am ET
Teligent, Inc. Announces First Quarter 2020 Results
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2020. First Quarter 2020 Highlights Net Revenues for the first quarter of 2020...
May 19, 2020 05:00 pm ET
Teligent, Inc. to Hold Conference Call for First Quarter 2020 Results on Friday May 22nd, 2020
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Friday May 22nd, 2020 to discuss the 1st quarter 2020 financial results and business update. The...
Apr 08, 2020 07:30 am ET
TELIGENT, INC. ANNOUNCES FOURTH QUARTER AND YEAR END 2019 RESULTS & AMENDMENTS TO EXISTING SECURED CREDIT FACILITIES
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2019. Fourth Quarter 2019 Highlights Net Revenues for the quarter...
Apr 03, 2020 04:05 pm ET
Teligent, Inc. to Hold Conference Call for Fourth Quarter and 2019 Full Year Financial Results on Wednesday April 8, 2020
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00 a.m. ET on Wednesday, April 8, 2020 to discuss the 4th quarter and 2019 full year financial results and...
Feb 05, 2020 08:22 am ET
Teligent, Inc. Announces Transition in Leadership
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced a transition in leadership. Teligent has announced that Jason Grenfell-Gardner will be stepping down...
Dec 23, 2019 05:12 pm ET
Teligent, Inc. Announces FDA Request for Further Data on Complex Drug
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its development partner has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its abbreviated...
Nov 13, 2019 12:30 pm ET
Teligent, Inc. to Present at Jefferies Global Healthcare Conference in London on Wednesday November 20, 2019
Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Jefferies Global Healthcare Conference. The Conference is taking place November 20-21, 2019 in London, UK. Jason Grenfell-Gardner,...
Nov 04, 2019 04:15 pm ET
Teligent, Inc. Announces Third Quarter 2019 Results
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Highlights Net revenues of $18.5 million for the...
Oct 31, 2019 04:30 pm ET
Teligent, Inc. to Hold Conference Call for Third Quarter 2019 Results on Monday November 4th, 2019
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 4:30pm ET on Monday November 4th, 2019 to discuss the 3rd quarter 2019 financial results and business update....
Oct 28, 2019 11:46 pm ET
Teligent Announces the Pricing of $34.4 Million of Series B Senior Convertible Notes
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the pricing of $34,405,000 aggregate principal amount of its 7.0% Cash / 8.0% PIK Series B Senior Unsecured...
Oct 28, 2019 02:16 pm ET
Teligent Announces First Injectable Filing From New Manufacturing Facility
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that it has filed a prior approval supplement (PAS) for ranitidine hydrochloride injection. This is the planned first injectable product to...
Oct 18, 2019 03:02 pm ET
Teligent, Inc. Announces FDA Approval of Gentamicin Sulfate Cream USP, 0.1% (Gentamicin Base)
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Oct 01, 2019 04:15 pm ET
Teligent Announces Strategic Review
Teligent Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that it has retained SVB Leerink as its financial advisor to assist with a strategic review of assets non-core to the Company’s long-term...
Aug 05, 2019 04:15 pm ET
Teligent, Inc. Announces Second Quarter 2019 Results
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2019. Second Quarter 2019 Highlights Net revenues of $18.3 million for the...
Aug 01, 2019 11:30 am ET
Teligent, Inc. to Hold Conference Call for Second Quarter 2019 Results on Monday August 5th, 2019
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Monday August 5th, 2019 to discuss the 2nd quarter 2019 financial results and business...
Jun 18, 2019 04:27 pm ET
Teligent, Inc. to Present at the Raymond James Life Sciences and MedTech Conference on June 19th 2019
Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Raymond James Life Sciences and MedTech Conference June 19, 2019. The Conference is taking place June 18th - June 19th, 2019 at...
Jun 18, 2019 11:30 am ET
Teligent, Inc. to Present at the Raymond James Life Sciences and MedTech Conference on June 19th 2019
Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Raymond James Life Sciences and MedTech Conference June 19, 2019. The Conference is taking place June 18th - June 19th, 2019 at...
Jun 14, 2019 03:00 pm ET
Teligent, Inc. (TLGT) Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Final Deadline: June 14, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against purchasers Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT) and certain of its officers, on behalf of...
Jun 14, 2019 11:01 am ET
FRIDAY DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ:
Jun 13, 2019 01:20 pm ET
FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ:
Jun 12, 2019 05:19 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teligent, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming June 14, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Teligent, Inc.  (“Teligent” or the “Company”) (NASDAQ: TLGT)...
Jun 12, 2019 12:26 pm ET
DEADLINE FRIDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ: TLGT) for violations of §§10(b) and 20(a) of the Securities Exchange...
Jun 11, 2019 10:00 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Teligent, Inc. (NASDAQ: TLGT) and Encourages Teligent Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Teligent, Inc. (NASDAQ: TLGT)...
Jun 11, 2019 03:26 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teligent, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 14, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT) investors who purchased...
Jun 07, 2019 03:00 pm ET
MWA, ORN & TLGT - Class Action Update from Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 05, 2019 07:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teligent, Inc. - TLGT
Pomerantz LLP is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jun 03, 2019 12:00 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ: TLGT) for violations of §§10(b) and 20(a) of the Securities Exchange...
May 31, 2019 03:00 pm ET
MWA, ORN & TLGT - Bronstein, Gewirtz & Grossman, LLC Class Action
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 30, 2019 04:09 pm ET
Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Actions Against Teligent, Inc. (TLGT) and June 14 Lead Plaintiff Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors that it has filed a class action lawsuit against Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT) and one of its executives for alleged violations
May 27, 2019 11:25 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ: TLGT) for violations of §§10(b) and 20(a) of the Securities Exchange...
May 26, 2019 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teligent, Inc. - TLGT
Pomerantz LLP is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
May 24, 2019 03:00 pm ET
MWA, ORN & TLGT - Bronstein, Gewirtz & Grossman, LLC Class Action
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 21, 2019 03:18 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Teligent, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teligent, Inc. ("Teligent" or the "Company")(NASDAQ:TLGT) of the June 14, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 21, 2019 01:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teligent, Inc. - TLGT
Pomerantz LLP is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
May 20, 2019 11:40 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ: TLGT) for violations of §§10(b) and 20(a) of the Securities Exchange...
May 16, 2019 08:26 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teligent, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 14, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Teligent, Inc.  (“Teligent” or the “Company”) (NASDAQ: TLGT) investors who purchased...
May 16, 2019 03:00 pm ET
MWA, ORN & TLGT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 15, 2019 03:34 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teligent, Inc. - TLGT
Pomerantz LLP is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
May 13, 2019 04:05 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Teligent, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teligent, Inc. ("Teligent" or the "Company")(NASDAQ:TLGT) of the June 14, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 13, 2019 10:42 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ: TLGT) for violations of §§10(b) and 20(a) of the Securities Exchange...
May 12, 2019 09:29 am ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors Who Suffered Large Investment Losses to Contact the Firm
SAN DIEGO, May 12, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased a common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as
May 10, 2019 11:20 am ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ:
May 09, 2019 03:00 pm ET
Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action - MWA, ORN & TLGT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 09, 2019 02:03 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ:
May 07, 2019 05:16 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Teligent, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teligent, Inc. ("Teligent" or the "Company")(NASDAQ:TLGT) of the June 14, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 06, 2019 05:43 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teligent, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 14, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: 
May 06, 2019 04:15 pm ET
Teligent, Inc. Announces First Quarter 2019 Results
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2019. First Quarter 2019 Highlights Net revenues of $13.1 million for the...
May 03, 2019 03:39 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teligent, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming June 14, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT) securities between May 2, 2017 and November 7, 2017, inclusive
May 02, 2019 03:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teligent, Inc. - TLGT
Pomerantz LLP is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
May 02, 2019 02:15 pm ET
Teligent, Inc. to Hold Conference Call for First Quarter 2019 Results on Monday May 6th, 2019
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Monday May 6th, 2019 to discuss the 1st  quarter 2019 financial results and business...
May 01, 2019 05:30 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Teligent, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Teligent, Inc.(“Teligent” or the “Company”) (NASDAQ:
May 01, 2019 01:03 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Teligent, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teligent, Inc. ("Teligent" or the "Company")(NASDAQ:TLGT) of the June 14, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
Apr 30, 2019 05:18 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Teligent, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teligent, Inc. ("Teligent" or the "Company")(NASDAQ:TLGT) of the June 14, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Apr 26, 2019 03:33 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Teligent, Inc. Investors (TLGT)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT) securities between May 2, 2017 and November 7, 2017, inclusive (the “Class Period”). Teligent investors have until June 14, 20
Apr 25, 2019 06:49 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Teligent, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teligent, Inc. ("Teligent" or the "Company")(NASDAQ:TLGT) of the June 14, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
Apr 25, 2019 06:13 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Teligent, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ:
Apr 25, 2019 03:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teligent, Inc. - TLGT
Pomerantz LLP is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Apr 24, 2019 05:13 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Teligent, Inc. Investors (TLGT)
Law Offices of Howard G. Smith announces an investigation on behalf of Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT) investors concerning the Company and its officers’ possible violations of federal securities laws.
Apr 24, 2019 03:00 pm ET
MWA, ORN & TLGT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 23, 2019 07:08 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teligent, Inc. - TLGT
NEW YORK, April 23, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teligent, Inc. ("Teligent" or the "Company") (NASDAQ: TLGT).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Apr 22, 2019 05:37 pm ET
Robbins Arroyo LLP: Teligent, Inc. (TLGT) Misled Shareholders According to a Recently Filed Lawsuit
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Teligent, Inc. (NASDAQ: TLGT) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between May 2, 2017 and November 7, 2017. Teligent is specialty generic pharmaceutical company.
Apr 22, 2019 05:02 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Teligent, Inc. To Contact The Firm
NEW YORK, April 22, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teligent, Inc. ("Teligent" or the "Company")(NASDAQ:TLGT) of the June 14, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Apr 22, 2019 08:45 am ET
Teligent Provides Update on Orphan Drug Complete Response Letter
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that on April 16, 2019, its development partner has filed the response to the Complete Response Letter (“CRL”) it received on August 30th,...
Apr 19, 2019 08:50 am ET
Recent Analysis Shows Thomson Reuters, Morgan Stanley, Crown, BT Group, VOXX International, and Teligent Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Thomson Reuters Corp (NYSE:TRI), Morgan Stanley (NYSE:MS), Crown Holdings, Inc....
Apr 18, 2019 03:00 pm ET
SHAREHOLDER ALERT - Teligent, Inc. (TLGT) Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Plaintiff Deadline: June 14, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against purchasers Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT) and certain of its officers, on behalf of...
Apr 16, 2019 05:36 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Teligent, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teligent, Inc. ("Teligent" or the "Company") (NASDAQ:TLGT) of the June 14, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
Apr 15, 2019 07:11 pm ET
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Teligent, Inc. (TLGT)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT) and one of its executives (collectively, “Defendants”).
Apr 12, 2019 03:00 pm ET
Teligent, Inc. Management Comments on Recent Market Movements
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today provided commentary on the recent market movements in the price of its stock. “Teligent acknowledges that there have been significant negative...
Apr 04, 2019 08:54 am ET
Teligent, Inc. Announces FDA Approval of Fluocinonide Cream USP, 0.1%
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Mar 19, 2019 02:06 pm ET
Teligent, Inc. Announces FDA Approval of Fluocinonide Topical Solution USP, 0.05%
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Mar 18, 2019 07:45 am ET
Teligent, Inc. Announces Fourth Quarter and Year End 2018 Results
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2018. Fourth Quarter 2018 Highlights Net revenues of $16.8...
Mar 15, 2019 04:15 pm ET
Teligent, Inc. to Present at the 31st Annual ROTH Conference Tuesday March 19, 2019
Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at 31st Annual ROTH Conference March 19, 2019. The Conference is taking place March 17th - March 19th, 2019 at the Ritz Carlton Laguna...
Mar 14, 2019 08:15 am ET
Teligent, Inc. Announces FDA Approval of Desonide Ointment, 0.05%
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Mar 12, 2019 04:15 pm ET
Teligent, Inc. to Hold Conference Call for Fourth Quarter 2018 Results
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 8:00am ET on Monday, March 18th, 2019 to discuss the 4th quarter 2018 financial results and business...
Feb 27, 2019 01:08 pm ET
Teligent, Inc. to Present at The 8th Annual SVB Leerink Global Healthcare Conference Friday March 1, 2019
Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at The 8th Annual SVB Leerink Global Healthcare Conference March 1, 2019. The Conference is taking place February 27th-March 1st, 2019 at...
Jan 24, 2019 08:30 am ET
Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Ointment USP, 0.05%
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Jan 02, 2019 08:30 am ET
Teligent, Inc. Announces FDA Approval of Gentamicin Sulfate Ointment USP, 0.1%
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Dec 13, 2018 06:33 pm ET
Teligent, Inc. Executes $120 Million Financing Agreement
Teligent, Inc. (NASDAQ: TLGT), (“Teligent” or the “Company”) announced today that on December 13, 2018 the Company entered into a definitive first lien revolving credit agreement with ACF Finco I LP, a limited partnership affiliated with Ares...
Dec 03, 2018 07:50 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Caesars Entertainment, Intercept Pharmaceuticals, Exxon Mobil, Teligent, Amerco, and Mettler-Toledo International — New Research Emp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caesars Entertainment Corporation (NASDAQ:CZR), Intercept Pharmaceuticals,...
Nov 16, 2018 05:15 pm ET
Teligent, Inc. Receives Notification of Deficiency From NASDAQ Related to the Delayed Filing of Form 10-Q
Teligent, Inc. (NASDAQ: TLGT), on November 13, 2018 received a standard notice from NASDAQ stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the quarterly period ended September 30, 2018, Teligent is not in...
Nov 13, 2018 04:15 pm ET
Teligent, Inc. Announces $120 Million Financing Commitment From Ares
Teligent, Inc. (NASDAQ: TLGT), (“Teligent” or the “Company”) announced today that the Company secured a financing commitment from funds managed by Ares Management, L.P. (“Ares”) (NYSE: ARES), on November 12, 2018.  Pursuant to the commitment, Ares...
Nov 13, 2018 04:15 pm ET
Teligent, Inc. Announces Third Quarter 2018 Results
Teligent, Inc. (NASDAQ: TLGT) (the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2018. Third Quarter 2018 Highlights Total revenue of $18.3...
Nov 12, 2018 08:30 am ET
Teligent, Inc. to Hold Conference Call for Third Quarter 2018 Results
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Tuesday November 13th, 2018 to discuss the 3rd quarter 2018 financial results and business...
Nov 02, 2018 08:45 am ET
Teligent, Inc. to Present at Jefferies London Healthcare Conference on Wednesday November 14, 2018
Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Jefferies London Healthcare Conference. The Conference is taking place November 14-15, 2018 in London, UK. Jason Grenfell-Gardner,...
Oct 24, 2018 08:45 am ET
Teligent, Inc. Announces FDA Approval of Desoximetasone Ointment USP 0.05%
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Oct 24, 2018 08:15 am ET
New Research: Key Drivers of Growth for Cedar Realty Trust, Vonage, Symantec, Teligent, UGI, and Welbilt — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cedar Realty Trust, Inc. (NYSE:CDR), Vonage Holdings Corp. (NYSE:VG),...
Oct 17, 2018 08:45 am ET
Teligent, Inc. Announces FDA Approval of Fluocinonide Cream USP, 0.05%
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Oct 02, 2018 08:56 am ET
Teligent, Inc. Announces FDA Approval of Fluocinonide Ointment USP, 0.05%
Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Aug 16, 2018 04:30 pm ET
Teligent Secures Critical Supply during Canadian National Drug Crisis despite Worldwide Shortage
Teligent, Inc. (NASDAQ:TLGT) (“Teligent”), a specialty generic pharmaceutical company, averted a national sterile water and sodium chloride crisis by securing inventory to cover 100% of the Canadian Market following a breakdown in the global supply...
Aug 14, 2018 08:30 am ET
Teligent Secures Critical Supply during Canadian National Drug Crisis despite Worldwide Shortage
TORONTO, Aug. 14, 2018 /CNW/ - Teligent, Inc. (NASDAQ:TLGT) ("Teligent"), a specialty generic pharmaceutical company, averted a national sterile water and sodium chloride crisis by securing inventory to cover 100% of the Canadian Market following a breakdown in the global supply chain.
Aug 08, 2018 04:15 pm ET
Teligent, Inc. Announces Second Quarter 2018 Results
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2018. Second Quarter 2018 Highlights The Company adopted ASC 606: Revenue from...
Aug 03, 2018 08:30 am ET
Teligent, Inc. to Hold Conference Call for Second Quarter 2018 Results
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Wednesday August 8, 2018 to discuss the 2nd quarter 2018 financial results and business...
Jul 30, 2018 08:30 am ET
Teligent, Inc. Announces FDA Approval of Hydrocortisone Lotion USP, 2.5%
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Jul 24, 2018 03:03 pm ET
Teligent, Inc. Announces FDA Approval of Hydrocortisone Cream USP, 2.5%
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Jul 02, 2018 08:00 am ET
Teligent, Inc. Announces FDA Approval of Lidocaine and Prilocaine Cream USP, 2.5%/2.5%
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Jun 29, 2018 07:35 am ET
New Research: Key Drivers of Growth for Webster Financial, Chimerix, Commerce Bancshares, Teligent, Pinnacle Financial Partners, and Empire State Realty Trust — Factors of Influence, Major Initiatives
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Webster Financial Corporation (NYSE:WBS), Chimerix, Inc. (NASDAQ:CMRX),...
Jun 20, 2018 09:22 am ET
Teligent, Inc. Announces FDA Approval of Fluocinonide Gel, 0.05%
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Jun 13, 2018 04:40 pm ET
Teligent, Inc. Announces FDA Approval of Diflorasone Diacetate Ointment 0.05%
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of...
Jun 05, 2018 04:45 pm ET
Teligent, Inc. Announces Closing Of $25 Million Secured Credit Facility
TELIGENT, Inc. (NASDAQ:TLGT) Teligent, Inc. (“Teligent”) announced today that it has entered into a Credit Agreement with certain funds managed by Highbridge Capital Management, LLC, an existing stakeholder, on June 1, 2018.  Pursuant to the...
May 17, 2018 07:30 am ET
Investor Expectations to Drive Momentum within Sun Communities, Anheuser-Busch InBev SA/NV, New Media Investment Group, Teligent, AptarGroup, and Pinnacle Financial Partners — Discovering Underlying F
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sun Communities, Inc. (NYSE:SUI), Anheuser-Busch InBev SA/NV (NYSE:BUD),...
May 08, 2018 08:00 am ET
Teligent, Inc. Announces First Quarter 2018 Results
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2018. First Quarter 2018 Highlights The Company adopted ASC 606: Revenue from...
May 07, 2018 06:36 pm ET
Teligent, Inc. to Present at Deutsche Bank’s 43rd Annual Health Care Conference on Tuesday, May 8, 2018
Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Deutsche Bank’s 43rd Annual Health Care Conference. The Conference is taking place May 8-9, 2018 at the Intercontinental Hotel, Boston....
May 07, 2018 05:50 pm ET
Teligent, Inc. to Reschedule Conference Call for First Quarter 2018 Results
Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, initially announced the Company would hold a conference call at 4:30pm ET on Monday, May 7, 2018 to discuss the 1st quarter 2018 financial results and...
May 01, 2018 04:30 pm ET
Teligent, Inc. to Present at Deutsche Bank’s 43rd Annual Health Care Conference on Tuesday May 8, 2018
BUENA, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Deutsche Bank’s 43rd Annual Health Care Conference. The Conference is taking place May 8-9, 2018...
Apr 27, 2018 09:25 am ET
Teligent, Inc. Announces Agreements to Exchange Approximately $65 million of its 3.75% Senior Convertible Notes Due 2019 for 4.75% Senior Convertible Notes Due 2023
BUENA, N.J., April 27, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT) (“Teligent”) announced today that it has entered into separate, privately negotiated exchange agreements with certain holders of Teligent’s 3.75% Senior Convertible Notes due 2019 (the “2019 Notes”). ...
Apr 26, 2018 02:15 pm ET
Teligent, Inc. to Hold Conference Call for First Quarter 2018 Results
BUENA, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Monday, May 7, 2018 to discuss the 1st...
Apr 17, 2018 04:35 pm ET
Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%
BUENA, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug...
Apr 06, 2018 10:32 am ET
Teligent, Inc. Announces FDA Approval of Ciclopirox Shampoo, 1%
BUENA, N.J., April 06, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug...
Mar 21, 2018 08:30 am ET
Teligent, Inc. Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%
BUENA, N.J., March 21, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug...
Mar 15, 2018 04:10 pm ET
Teligent, Inc. Announces Fourth Quarter and Year End 2017 Results
BUENA, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2017.
Mar 13, 2018 04:30 pm ET
Teligent, Inc. to Present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday March 20, 2018
BUENA, N.J., March 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Oppenheimer 28th Annual Healthcare Conference. The Conference is taking place March 20-21, 2018 at...
Mar 12, 2018 04:30 pm ET
Teligent, Inc. to Hold Conference Call for Fourth Quarter 2017 Results
BUENA, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Thursday March 15, 2018 to discuss the 4th...
Mar 05, 2018 04:30 pm ET
Teligent, Inc. to Present at the Raymond James 39th Annual Institutional Investors Conference on Wednesday March 7, 2018
BUENA, N.J., March 05, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Raymond James 39th Annual Institutional Investors Conference. The Conference is taking place March 4-7,...
Feb 14, 2018 09:31 am ET
Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%
BUENA, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug...
Feb 14, 2018 08:30 am ET
Investor Expectations to Drive Momentum within Amerco, Caesars Entertainment, Air Products and Chemicals, Consolidated Edison, Teligent, and Versartis — Discovering Underlying Factors of Influence
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amerco (NASDAQ:UHAL), Caesars Entertainment Corporation (NASDAQ:CZR),...
Jan 26, 2018 08:40 am ET
Teligent, Inc. Announces the Appointment of Damian Finio as Chief Financial Officer
BUENA, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced today that Damian Finio has been appointed Chief Financial Officer of Teligent, Inc., effective February 5, 2018. Mr. Finio...
Jan 03, 2018 03:55 pm ET
Teligent, Inc. to Present at the J.P. Morgan 36th Annual Healthcare Conference January 10th
BUENA, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the J.P. Morgan 36th Annual Healthcare Conference. The Conference is taking place January 8-11, 2018...
Nov 30, 2017 08:00 am ET
Report: Exploring Fundamental Drivers Behind Amerco, Caesars Entertainment, Air Products and Chemicals, Consolidated Edison, Teligent, and Versartis — New Horizons, Emerging Trends, and Upcoming Devel
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Amerco (NASDAQ:UHAL), Caesars Entertainment Corporation...
Nov 22, 2017 08:30 am ET
Teligent, Inc. Announces First FDA Generic Approval of Hydrocortisone Butyrate Lotion 0.1%
BUENA, N.J., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug...
Nov 21, 2017 08:30 am ET
Teligent, Inc. Announces FDA Approval of Erythromycin Topical Solution USP, 2%
BUENA, N.J., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug...
Nov 10, 2017 09:20 am ET
Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%
BUENA, N.J., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug...
Nov 06, 2017 04:05 pm ET
Teligent, Inc. Announces Third Quarter 2017 Results
BUENA, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2017....
Nov 06, 2017 04:05 pm ET
Teligent, Inc. Announces Third Quarter 2017 Results
BUENA, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2017.
Sep 18, 2017 04:45 pm ET
Teligent, Inc. Appoints Thomas J. Sabatino, Jr. to Board of Directors
BUENA, N.J., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Thomas J. Sabatino, Jr. to its Board of Directors.  Mr. Sabatino will also serve on the Company’s Audit Committee. ...
Jul 21, 2017 09:00 am ET
Teligent, Inc. Announces FDA Approval Of Erythromycin Topical Gel USP, 2%
BUENA, N.J., July 21, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Erythromycin Topical Gel USP, 2%.  This is Teligent's third approval for 2017, and its fourteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines. 
May 16, 2017 09:00 am ET
Teligent, Inc. To Present At Bank Of America Merrill Lynch Healthcare Conference Taking Place May 16, 2017
BUENA, N.J., May 16, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Bank of America Merrill Lynch Healthcare Conference taking place on May 16-18, 2017 at Encore at Wynn Las Vegas.
May 03, 2017 09:00 am ET
Teligent, Inc. To Present At Deutsche Bank 42nd Annual Health Care Conference On May 3, 2017
BUENA, N.J., May 3, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Deutsche Bank 42nd Annual Health Care Conference. The Conference is taking place on May 3-4, 2017 at the InterContinental Boston Hotel, Boston, MA.
May 02, 2017 05:10 pm ET
Teligent, Inc. Announces First Quarter 2017 Results
BUENA, N.J., May 2, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2017.
Apr 25, 2017 09:00 am ET
Teligent, Inc. Appoints Martin Wilson To General Counsel
BUENA, N.J., April 25, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Martin Wilson as its General Counsel. 
Apr 21, 2017 09:00 am ET
Teligent, Inc. To Hold Conference Call For 1st Quarter 2017 Results
BUENA, N.J., April 21, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Tuesday, May 2, 2017 to discuss the 1st quarter 2017 results.
Mar 22, 2017 09:00 am ET
Teligent, Inc. To Present At Oppenheimer 27th Annual Healthcare Conference On March 22, 2017
BUENA, N.J., March 22, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Oppenheimer 27th Annual Healthcare Conference. The Conference is taking place on March 21-22, 2017 at the Westin New York Grand Central, New York, NY.
Mar 13, 2017 10:18 am ET
Teligent, Inc. To Present At 29th Annual ROTH Conference On March 13, 2017
BUENA, N.J., March 13, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the 29th Annual ROTH Conference. The Conference is taking place on March 12-15, 2017 at The Ritz Carlton, Dana Point, CA.
Mar 08, 2017 08:00 am ET
Teligent, Inc. Announces FDA Approval Of Clobetasol Propionate Gel, 0.05%
BUENA, N.J., March 8, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Gel, 0.05%.  This is Teligent's second approval for 2017, and its thirteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines. 
Mar 07, 2017 04:01 pm ET
Teligent, Inc. Announces Fourth Quarter And Year-End 2016 Results
BUENA, N.J., March 7, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2016.
Mar 06, 2017 08:00 am ET
Teligent, Inc. Announces FDA Approval Of Triamcinolone Acetonide Ointment USP, 0.5%
BUENA, N.J., March 6, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Triamcinolone Acetonide Ointment USP, 0.5%.  This is Teligent's first approval for 2017, and its twelfth approval from its internally-developed pipeline of topical generic pharmaceutical medicines. 
Mar 01, 2017 08:00 am ET
Teligent, Inc. To Hold Conference Call For 4th Quarter And Year End 2016 Results
BUENA, N.J., March 1, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30 pm ET on Tuesday, March 7, 2017 to discuss the 4th quarter and year end 2016 results.
Jan 10, 2017 08:00 am ET
Teligent, Inc. To Present At 35th Annual J.P. Morgan Healthcare Conference On January 11, 2017
BUENA, N.J., Jan. 10, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the 35th Annual J.P. Morgan Healthcare Conference. The Conference is taking place on January 9-12, 2017 at the Westin St. Francis Hotel, San Francisco, CA.
Jan 03, 2017 08:00 am ET
Teligent, Inc. Announces FDA Approval For Three Abbreviated New Drug Applications
BUENA, N.J., Jan. 3, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of three of the Company's abbreviated new drug applications (ANDAs) from the U.S. Food and Drug Administration (FDA) of Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram and 1 mg/gram, Clindamycin Phosphate Topical Solution USP, 1% and Flurandrenolide Ointment USP, 0.05%.  These approvals were received on December 30, 2016 and brings Teligent's total approvals from its internally developed pipeline o
Nov 30, 2016 09:25 am ET
Teligent, Inc. Announces FDA Approval Of Clobetasol Propionate Lotion 0.05%
BUENA, N.J., Nov. 30, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Lotion 0.05%.  This is Teligent's sixth approval from its internally developed pipeline of topical generic pharmaceutical products. 
Nov 16, 2016 08:00 am ET
Teligent, Inc. Ranked 200 Fastest Growing Company in North America on Deloitte's 2016 Technology Fast 500™
BUENA, N.J., Nov. 16, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it ranked No. 200 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. The Deloitte Technology Fast 500 is based on percentage of revenue growth from fiscal year 2012 to 2015, and Teligent, Inc. grew by 417 percent during this period. The company also appeared on the Fast 500 list in 2014 and 2015.
Nov 16, 2016 08:00 am ET
Teligent, Inc. To Present At 7th Annual Craig-Hallum Alpha Select Conference On November 16, 2016
BUENA, N.J., Nov. 16, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company will present today at the 7th Annual Craig-Hallum Alpha Select Conference. The Conference will take place on November 16-17, 2016 at the Sheraton New York Times Square Hotel, New York, NY.
Oct 27, 2016 05:02 pm ET
Teligent, Inc. Announces Third Quarter 2016 Results
BUENA, N.J., Oct. 27, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2016.
Oct 14, 2016 09:00 am ET
Teligent, Inc. To Hold Conference Call For 3rd Quarter 2016 Results
BUENA, N.J., Oct. 14, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30 pm ET on Thursday, October 27, 2016 to discuss the 3rd quarter 2016 results.
Oct 11, 2016 09:00 am ET
Teligent, Inc. Announces The Opening Of A Product Development Laboratory In Estonia
TALLINN, Estonia, Oct. 11, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced today that it has opened a pharmaceutical Product Development laboratory in Estonia.  The GMP-compliant lab will support the development of topical and injectable pharmaceutical products for the company's North American markets.
Oct 05, 2016 09:00 am ET
Second Teligent Topical Product Approved by Health Canada
BUENA, N.J., Oct. 5, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that its Estonian subsidiary, Teligent OÜ, has received approval from Health Canada's Therapeutic Products Directorate for Lidocaine Ointment USP 5%.  This is the sixth approval for Teligent OÜ this calendar year and will be distributed by Teligent's business in Canada.
Sep 30, 2016 09:00 am ET
Health Canada Approves First Teligent Topical Product
BUENA, N.J., Sept. 30, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that its Estonian subsidiary, Teligent OÜ, has received approval from Health Canada's Therapeutic Products Directorate for Lidocaine Hydrochloride Topical Solution USP.  This is the fifth approval for Teligent OÜ this calendar year and will be distributed by Teligent's business in Canada.
Sep 13, 2016 09:00 am ET
Teligent, Inc. To Present At Morgan Stanley Global Healthcare Conference On September 13, 2016
BUENA, N.J., Sept. 13, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference. The Conference takes place at the Grand Hyatt NY, New York, NY.
Aug 25, 2016 09:00 am ET
Teligent, Inc. Announces Health Canada Approval Of Three Baclofen Injection Products
BUENA, N.J., Aug. 25, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that its Estonian subsidiary, Teligent OÜ, has received three Abbreviated New Drug Submission (ANDS) approvals from Health Canada's Therapeutic Products Directorate for Baclofen Injection 0.05mg/mL, Baclofen Injection 0.5mg/mL and Baclofen Injection 2mg/mL. These are the second, third and fourth drug approvals for Teligent OÜ and will be distributed by Teligent's business in Canada.
Aug 23, 2016 09:00 am ET
Teligent, Inc. Announces Health Canada Approval Of Gentamicin Injection USP
BUENA, N.J., Aug. 23, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that its Estonian subsidiary, Teligent OÜ, has received approval of the Company's New Drug Submission (NDS) from Health Canada's Therapeutic Products Directorate for Gentamicin Injection USP 40mg/mL in 2mL ampoules.  This is the first drug approval for Teligent OÜ and will be distributed by Teligent's business in Canada.
Jul 28, 2016 05:50 pm ET
Teligent, Inc. Announces Second Quarter 2016 Results
BUENA, N.J., July 28, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2016.
Jul 13, 2016 09:00 am ET
Teligent, Inc. To Hold Conference Call For 2nd Quarter 2016 Results
BUENA, N.J., July 13, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 28, 2016 to discuss the 2nd quarter 2016 results.
Jul 08, 2016 09:00 am ET
Teligent, Inc. Receives Two FDA Approvals For Topical Prescription Portfolio
BUENA, N.J., July 8, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced today that it has received approvals of the Company's abbreviated new drug applications (ANDAs) from the U.S. Food and Drug Administration (FDA) for both Triamcinolone Acetonide Lotion USP, 0.1% and Triamcinolone Acetonide Lotion USP, 0.025%.  The FDA has now approved seven ANDAs from the Company's internally developed pipeline of topical generic pharmaceutical products.
Jul 06, 2016 09:00 am ET
Teligent, Inc. Advances $50 Million Facility Expansion
BUENA, N.J., July 6, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, recently held the formal groundbreaking ceremony for the ongoing expansion of its manufacturing and research and development complex in Buena, NJ. The $45-50 million project will increase the facility's footprint by more than 75,000 square feet, a 200% increase to current operations. Once completed, the expansion will include the installation of a new isolator-based sterile injectable manufacturing suite and will deliver a significant increase to the company's
Jun 21, 2016 09:00 am ET
Teligent, Inc. To Present At JMP Securities Life Sciences Conference On June 21, 2016
BUENA, N.J., June 21, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the JMP Securities Life Sciences Conference. The Conference will take place June 21-22, 2016 at The St. Regis New York, New York, NY.
May 16, 2016 09:00 am ET
Teligent, Inc. Announces FDA Approval Of Triamcinolone Acetonide Ointment USP, 0.1%
BUENA, N.J., May 16, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced today that it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Triamcinolone Acetonide Ointment USP, 0.1%.  This is Teligent's fifth approval from its internally developed pipeline of topical generic pharmaceutical products. 
May 10, 2016 09:00 am ET
Teligent, Inc. To Present At Bank of America Merrill Lynch Annual Health Care Conference On May 10, 2016
BUENA, N.J., May 10, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference. The Conference will take place May 10-12, 2016 at the Encore at Wynn, Las Vegas, Nevada.
May 03, 2016 09:00 am ET
Teligent, Inc. To Present At Deutsche Bank 41st Annual Health Care Conference On May 4, 2016
BUENA, N.J., May 3, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Deutsche Bank 41st Annual Health Care Conference. The Conference will take place May 4-5, 2016 at The InterContinental Hotel, Boston, MA.
Apr 28, 2016 05:05 pm ET
Teligent, Inc. Announces First Quarter 2016 Results
BUENA, N.J., April 28, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2016.
Apr 14, 2016 09:00 am ET
Teligent, Inc. To Hold Conference Call For 1st Quarter 2016 Results
BUENA, N.J., April 14, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, April 28, 2016 to discuss the 1st quarter 2016 results.
Mar 31, 2016 10:30 am ET
Teligent, Inc. Appoints Dr. Carole Ben-Maimon To Board Of Directors
BUENA, N.J., March 31, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Dr. Carole Ben-Maimon to its Board of Directors.  Dr. Ben-Maimon will also serve on the Company's Compensation and Nominating Committees. 
Mar 21, 2016 09:00 am ET
Teligent, Inc. Announces Launch Of Cefotan® (Cefotetan For Injection)
BUENA, N.J., March 21, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has launched Cefotan® (cefotetan for injection). This is the Company's first product launched from the portfolio of discontinued and withdrawn new drug applications (NDAs) and abbreviated new drug applications (ANDAs), which the Company purchased from AstraZeneca on September 25, 2014.
Mar 14, 2016 03:01 pm ET
Teligent, Inc. To Present At Roth Capital Partners 28th Annual Growth Stock Conference On March 14, 2016
BUENA, N.J., March 14, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Roth Capital Partners 28th Annual Growth Stock Conference. The Conference will take place on March 13-16, 2016 at The Ritz Carlton, Dana Point, California.
Mar 09, 2016 04:05 pm ET
Teligent, Inc. Announces Fourth Quarter And Year-End 2015 Results
BUENA, N.J., March 9, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2015.
Feb 26, 2016 08:00 am ET
Teligent, Inc. Announces FDA Approval Of Desoximetasone Ointment USP 0.25%
BUENA, N.J., Feb. 26, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort® Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc. This is Teligent's fourth approval from its internally developed pipeline of topical generic pharmaceutical products. 
Feb 25, 2016 08:00 am ET
Teligent, Inc. To Hold Conference Call For 4th Quarter And Year End 2015 Results
BUENA, N.J., Feb. 25, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Wednesday, March 9, 2016 to discuss the 4th quarter and year end 2015 results.
Feb 02, 2016 08:00 am ET
Teligent, Inc. Announces FDA Approval Of Lidocaine Ointment USP 5%
BUENA, N.J., Feb. 2, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Lidocaine Ointment USP 5%. This is Teligent's third approval from its internally developed pipeline of generic pharmaceutical products.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.